News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Eli Lilly and Company Reports Third-Quarter 2012 Results
October 24, 2012
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Worldwide revenue declined 11 percent to $5.443 billion, driven by Zyprexa patent expirations. Cymbalta revenue increased 16 percent due to continued growth in both the U.S. and international markets.
Twitter
LinkedIn
Facebook
Email
Print
Earnings
Eli Lilly and Company
MORE ON THIS TOPIC
Layoff Tracker
Nurix Cuts Unknown Number of Employees Following Operational Review
November 21, 2025
·
91 min read
·
BioSpace Editorial Staff
Legal
UPDATE: GSK’s Tesaro Sues AnaptysBio Over Current Jemperli Contract; Anaptys Countersues
November 21, 2025
·
3 min read
·
Tristan Manalac
Pipeline
Moderna Cans 3 mRNA Vaccines, Secures $1.5B Loan in Quest for 10% Growth
November 21, 2025
·
2 min read
·
Tristan Manalac
Funding
Aspen’s $115M Series C Opens Doors to Late-Stage Development for Parkinson’s Program
November 20, 2025
·
1 min read
·
Tristan Manalac
